Bluebird’s Improved Vector Yields Promising Early Phase II Data In Beta Thalassemia
This article was originally published in The Pink Sheet Daily
Two patients achieve independence from transfusions and show normalizing levels of hemoglobin in Phase II trial of experimental viral vector-based gene therapy. Bluebird’s share price soared on the promising news.
You may also be interested in...
The gene therapy start-up taps diversified public and private investors, as well as strategic backer Shire, for one of the year’s biggest rounds of private capital funding for a biotech thus far.
Johnson & Johnson has achieved exceptional growth in recent years, and a raft of new products is set to sustain it further.